Active, Not Recruiting
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs - IM011-054
Updated: 26 September, 2024 | ClinicalTrials.gov
Phase
Gender(s)
Age Range
Active, Not Recruiting
Inclusion Criteria - Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at screening. - Meets the Classification Criteria for Psoriatic Arthritis at Screening. - Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at screening. - Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and day 1. - Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening. - ≥ 1 PsA-related hand and/or foot joint erosion on X-ray during Screening Period that is confirmed by central reading. - Must have completed the week 52 treatment for the optional open-label long-term extension period. Exclusion Criteria - Nonplaque psoriasis at screening or day 1. - Other autoimmune condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis. - History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease). - Active fibromyalgia. - Received an approved or investigational biologic therapy for the treatment of PsA or PsO. - Other protocol-defined Inclusion/Exclusion criteria apply.
If you want to report a side effect, you can report directly to the Danish Medicines Agency via the website www.meldenbivirkning.dk
We recommend that you also contact BMS to report side effects.
Side effects and other reportable events are defined here
Report side effects or product quality complaints: Medical Information
466-DK-2200001
